Mitchell SG, Monico LB, Gryczynski J, et al. - Via this two-group randomized controlled trial, researchers aimed at investigating the effectiveness of extended-release naltrexone (XR-NTX) for the treatment of opioid use disorder (OUD) among adolescents and young adults. A total of 288 youth, ages 15–21, with moderate/severe OUD from a residential addiction treatment program were randomized to receive either XR-NTX or treatment-as-usual (TAU; either buprenorphine maintenance treatment or treatment without OUD medication following medically managed withdrawal) prior to discharge, with continued treatment in the community for 6 months. Findings revealed significant participant non-adherence to allocated treatment. All study arm effects were non-significant in the intention-to-treat analyses. At 3 and 6-month follow-up, fewer days opioid use were observed in correlation with receipt of XR-NTX.